Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BMS’ ixabepilone shows activity in breast cancer patients
According to the company, there are currently few proven treatment options available to patients with breast cancer whose disease has rapidly progressed through or is not responding to
According to the company, there are currently few proven treatment options available to patients with breast cancer whose disease has rapidly progressed through or is not responding to
The compound, MIV-170, did not meet the profile desired by Bristol-Myers Squibb, according to the company. MIV-170 belongs to a group of polymerase inhibitors that Medivir’s subsidiary, Medivir
Results from the primary analysis of the Phase III study showed that 77% of treatment-experienced HIV-1 infected adults taking Prezista (darunavir) 600mg tablets with 100mg Prezista/r (ritonavir) twice
The study will evaluate the prophylactic use of Camvia in patients undergoing a liver transplant procedure, and will be conducted in up to 60 US transplant centers. The
The placebo controlled trial, conducted at 22 hospitals across Australia, New Zealand and the UK, evaluated the impact of Bronchitol on mucus clearance, disease symptoms, cough severity, exercise
Patients have now progressed into the open-label section of the trial (weeks 24 to 48) and will continue to receive 800mg apricitabine twice a day as part of
The pivotal hylastan trial involved nearly 400 patients with osteoarthritis of the knee enrolled at 27 sites in North America and Europe. Patients were randomized to receive two
The company had planned to have the system up and running by late summer. UniChem and AAH Pharmaceuticals were appointed as distribution partners in April. The system replaces
The phase I trial is an accelerated titration dose-escalation study designed to assess the safety and tolerability of MP470, and to determine the maximum tolerated dose of the
The company said that the decision to end the Lomucin trial was made when it determined that there would be no additional benefit to further enrollment. Genaera plans